Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02875314 · ClinicalTrials.gov registry record · Phase 4
HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors
A Phase 4 study of Medulloblastoma and Central Nervous System Embryonal Tumors, sponsored by Parth Patel.
- Active
- Registry status
- Phase 4
- Development phase
- 250
- Enrollment target
- 20
- Study locations
NCT02875314 is a Phase 4 study of Medulloblastoma and Central Nervous System Embryonal Tumors that is active but no longer recruiting, run by Parth Patel. The registered enrollment target is 250 participants, above the 132-participant average among 29 other Medulloblastoma trials with a reported enrollment target (89% higher). The trial reports 20 study locations across 11 states.
The verdict
NCT02875314, a Phase 4 study of Medulloblastoma and Central Nervous System Embryonal Tumors, is active but no longer recruiting, sponsored by Parth Patel.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 250 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a prospective randomized clinical trial, to determine whether dose-intensive tandem Consolidation, in a randomized comparison with single cycle Consolidation, provides an event-free survival (EFS) and overall survival (OS). The study population will be high-risk patients (non-Wnt and non-Shh sub-groups) with medulloblastoma, and for all patients with central nervous system (CNS) embryonal tumors completing "Head Start 4" Induction. This study will further determine whether the additional labor intensity (duration of hospitalizations and short-term and long-term morbidities) associated with the tandem treatment is justified by the improvement in outcome. It is expected that the tandem (3 cycles) Consolidation regimen will produce a superior outcome compared to the single cycle Consolidation, given the substantially higher dose intensity of the tandem regimen, without significant addition of either short-term or long-term morbidities.
Conditions Studied
Interventions
- DRUG Induction
- DRUG Single Cycle Intensive Chemotherapy
- DRUG Tandem 3 Cycle Intensive Chemotherapy
Study Locations (20)
California
- Loma Linda University Medical Center - Loma Linda
- Memorial Care Health Services - Long Beach
- Children's Hospital Los Angeles - Los Angeles
- Mattel Children's Hospital (UCLA) - Los Angeles
- UCSF Oakland Benioff - Oakland
- Children's Hospital Orange County - Orange
Florida
- Shands Children's Hospital/ University of FL - Gainesville
- Nemours Center for Cancer and Blood Disorders - Jacksonville
- Nicklaus Children's Hospital - Miami
- Orlando Health - Orlando
- John's Hopkins All Children's Hospital - St. Petersburg
Alabama
- Children's of Alabama - Birmingham
Arizona
- Phoenix Children's Hospital - Phoenix
Arkansas
- Arkansas Children's Hospital - Little Rock
Colorado
- Children's Hospital Colorado - Aurora
Delaware
- Nemours Center for Cancer and Blood Disorders - Wilmington
District of Columbia
- Children's National Medical Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2015-09 |
| Est. Completion | 2030-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02875314
The ClinicalTrials.gov registry entry for NCT02875314 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 132-participant average among 29 other Medulloblastoma trials with a reported enrollment target (89% higher). The listed sponsor is Parth Patel, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Medulloblastoma appearing as the primary indexed condition, and to 3 interventions - of which Induction is the first listed.
NCT02875314 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT02875314 about?
NCT02875314 is a clinical study titled "HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors". This is a prospective randomized clinical trial, to determine whether dose-intensive tandem Consolidation, in a randomized comparison with single cycle Consolidation, provides an event-free survival (EFS) and overall survival (OS). The study population will be high-risk patients (non-Wnt and non-Shh...
What is the current status of trial NCT02875314?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 250 participants. The study started on 2015-09. Estimated completion is 2030-12.
What conditions does trial NCT02875314 study?
This clinical trial studies the following conditions: Medulloblastoma, Central Nervous System Embryonal Tumors.
What interventions are being tested in trial NCT02875314?
The interventions under investigation include: Induction (DRUG), Single Cycle Intensive Chemotherapy (DRUG), Tandem 3 Cycle Intensive Chemotherapy (DRUG).
Who is sponsoring clinical trial NCT02875314?
This trial is sponsored by Parth Patel, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02875314 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Medulloblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.
RECRUITING · Phase 4
-
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
RECRUITING · Phase 2
-
Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma
RECRUITING · NA
-
Atovaquone Combined With Radiation in Children With Malignant Brain Tumors
RECRUITING · Phase 1
-
Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
RECRUITING · Phase 2
-
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.